Clinical-stage biopharmaceutical company developing novel, first-in-class therapies for aggressive and treatment-resistant cancers
Clinical-stage biopharmaceutical company developing novel, first-in-class therapies for aggressive and treatment-resistant cancers. Its lead programs include CDK7 and CDK12/13 inhibitors and a Cyclin-K degrader, targeting mechanisms involved in cancer progression and resistance.